IR@PKUHSC  > 北京大学第三临床医学院
学科主题临床医学
Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial
Zheng, Jin-Ping1; Wen, Fu-Qiang2; Bai, Chun-Xue3; Wan, Huan-Ying4; Kang, Jian5; Chen, Ping6; Yao, Wan-Zhen7; Ma, Li-Jun8; Li, Xia9; Raiteri, Luca10; Sardina, Marco10; Gao, Yi1; Wang, Bai-Song11; Zhong, Nan-Shan1; PANTHEON Study Grp
刊名LANCET RESPIRATORY MEDICINE
2014-03-01
DOI10.1016/S2213-2600(13)70286-8
2期:3页:187-194
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Respiratory System
资助者Hainan Zambon Pharmaceutical ; Hainan Zambon Pharmaceutical
研究领域[WOS]Respiratory System
关键词[WOS]FLUTICASONE PROPIONATE ; CHINESE PATIENTS ; COPD ; EFFICACY ; SALMETEROL ; CARBOCISTEINE ; SAFETY ; 1-YEAR
英文摘要

Background Increased oxidative stress and inflammation has a role in the pathogenesis of chronic obstructive pulmonary disease (COPD). Drugs with antioxidant and anti-inflammatory properties, such as N-acetylcysteine, might provide a useful therapeutic approach for COPD. We aimed to assess whether N-acetylcysteine could reduce the rate of exacerbations in patients with COPD.

Methods In our prospective, randomised, double-blind, placebo-controlled, parallel-group study, we enrolled patients aged 40-80 years with moderate-to-severe COPD (post-bronchodilator forced expiratory volume in 1 s [FEV1]/forced vital capacity <0.7 and FEV1 of 30-70% of predicted) at 34 hospitals in China. We stratified patients according to use of inhaled corticosteroids (regular use or not) at baseline and randomly allocated them to receive N-acetylcysteine (one 600 mg tablet, twice daily) or matched placebo for 1 year. The primary endpoint was the annual exacerbation rate in patients who received at least one dose of study drug and had at least one assessment visit after randomisation. This study is registered with the Chinese Clinical Trials Registry, ChiCTR-TRC-09000460.

Findings Between June 25, 2009, and Dec 29, 2010, we screened 1297 patients, of whom 1006 were eligible for randomisation (504 to N-acetylcysteine and 502 to placebo). After 1 year, we noted 497 acute exacerbations in 482 patients in the N-acetylcysteine group who received at least one dose and had at least one assessment visit (1.16 exacerbations per patient-year) and 641 acute exacerbations in 482 patients in the placebo group (1.49 exacerbations per patient-year; risk ratio 0.78, 95% CI 0.67-0.90; p=0.0011). N-acetylcysteine was well tolerated: 146 (29%) of 495 patients who received at least one dose of N-acetylcysteine had adverse events (48 serious), as did 130 (26%) of 495 patients who received at least one dose of placebo (46 serious). The most common serious adverse event was acute exacerbation of COPD, occurring in 32 (6%) of 495 patients in the N-acetylcysteine group and 36 (7%) of 495 patients in the placebo group.

Interpretation Our findings show that in Chinese patients with moderate-to-severe COPD, long-term use of N-acetylcysteine 600 mg twice daily can prevent exacerbations, especially in disease of moderate severity. Future studies are needed to explore efficacy in patients with mild COPD (GOLD I).

语种英语
资助者Hainan Zambon Pharmaceutical ; Hainan Zambon Pharmaceutical
WOS记录号WOS:000336715100016
引用统计
被引频次:74[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/62158
专题北京大学第三临床医学院
作者单位1.Peking Univ, Hosp 3, Beijing 100871, Peoples R China
2.Henan Prov Peoples Hosp, Zhengzhou, Peoples R China
3.Hainan Zambon Pharmaceut, Beijing, Peoples R China
4.Zambon, Innovat & Med Sci Dept, Milan, Italy
5.MedKey Med Tec Dev, Shanghai, Peoples R China
6.Shenyang PLA Gen Hosp, Shenyang, Peoples R China
7.Guangzhou Med Univ, Affiliated Hosp 1, Natl Clin Res Ctr Resp Dis, State Key Lab Resp Dis,Guangzhou Inst Resp Dis, Guangzhou, Guangdong, Peoples R China
8.Sichuan Univ, West China Hosp, Chengdu 610064, Peoples R China
9.Fudan Univ, Zhongshan Hosp, Shanghai 200433, Peoples R China
10.China Med Univ, Affiliated Hosp 1, Shenyang, Peoples R China
11.Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp, Shanghai 200030, Peoples R China
推荐引用方式
GB/T 7714
Zheng, Jin-Ping,Wen, Fu-Qiang,Bai, Chun-Xue,et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial[J]. LANCET RESPIRATORY MEDICINE,2014,2(3):187-194.
APA Zheng, Jin-Ping.,Wen, Fu-Qiang.,Bai, Chun-Xue.,Wan, Huan-Ying.,Kang, Jian.,...&PANTHEON Study Grp.(2014).Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.LANCET RESPIRATORY MEDICINE,2(3),187-194.
MLA Zheng, Jin-Ping,et al."Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial".LANCET RESPIRATORY MEDICINE 2.3(2014):187-194.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zheng, Jin-Ping]的文章
[Wen, Fu-Qiang]的文章
[Bai, Chun-Xue]的文章
百度学术
百度学术中相似的文章
[Zheng, Jin-Ping]的文章
[Wen, Fu-Qiang]的文章
[Bai, Chun-Xue]的文章
必应学术
必应学术中相似的文章
[Zheng, Jin-Ping]的文章
[Wen, Fu-Qiang]的文章
[Bai, Chun-Xue]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。